Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P)

Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study

Advances in Therapy ◽

10.1007/s12325-021-01899-0 ◽

2021 ◽

Author(s):

Lin Cai ◽

Linfeng Li ◽

Hao Cheng ◽

Yangfeng Ding ◽

Zhenshu Biao ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Severe Plaque Psoriasis ◽

Phase Iii Study

Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies

Drugs & Aging ◽

10.1007/s40266-018-0520-z ◽

2018 ◽

Vol 35 (2) ◽

pp. 135-144 ◽

Cited By ~ 23

Author(s):

Andreas Körber ◽

Charis Papavassilis ◽

Vaishali Bhosekar ◽

Maximilian Reinhardt

Keyword(s):

Plaque Psoriasis ◽

Pooled Analysis ◽

Phase Iii ◽

Elderly Subjects ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phase Iii Studies

Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

American Journal of Clinical Dermatology ◽

10.1007/s40257-018-0353-x ◽

2018 ◽

Vol 19 (3) ◽

pp. 457-457 ◽

Cited By ~ 1

Author(s):

Andrew Blauvelt ◽

Kim A. Papp ◽

Christopher E. M. Griffiths ◽

Luis Puig ◽

Jamie Weisman ◽

...

Keyword(s):

Clinical Trials ◽

Plaque Psoriasis ◽

Randomized Clinical Trials ◽

Phase Iii ◽

Efficacy And Safety ◽

Two Phase ◽

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

British Journal of Dermatology ◽

10.1111/bjd.14164 ◽

2015 ◽

Vol 173 (6) ◽

pp. 1387-1399 ◽

Cited By ~ 201

Author(s):

C. Paul ◽

J. Cather ◽

M. Gooderham ◽

Y. Poulin ◽

U. Mrowietz ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Plaque Psoriasis ◽

Controlled Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Phosphodiesterase 4 Inhibitor

Efficacy and safety of efalizumab in a large cohort of patients with moderate to severe plaque psoriasis: pooled results from randomized phase III trials

10.1016/j.jaad.2003.10.010 ◽

2004 ◽

Vol 50 (3) ◽

pp. P1 ◽

Cited By ~ 5

Author(s):

Kenneth Gordon ◽

David Pariser ◽

Richard Langley ◽

Ivor Caro

Keyword(s):

Plaque Psoriasis ◽

Large Cohort ◽

Phase Iii ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phase Iii Trials

A phase III open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results

10.1016/j.jaad.2021.08.066 ◽

2021 ◽

Author(s):

Nina Magnolo ◽

Külli Kingo ◽

Vivian Laquer ◽

John Browning ◽

Adam Reich ◽

...

Keyword(s):

Multicenter Study ◽

Plaque Psoriasis ◽

Pediatric Patients ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label ◽

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

10.1016/j.jaad.2015.03.049 ◽

2015 ◽

Vol 73 (1) ◽

pp. 37-49 ◽

Cited By ~ 273

Author(s):

Kim Papp ◽

Kristian Reich ◽

Craig L. Leonardi ◽

Leon Kircik ◽

Sergio Chimenti ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Plaque Psoriasis ◽

Controlled Trial ◽

Phase Iii ◽

Pde4 Inhibitor ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phosphodiesterase 4 ◽

Randomized Controlled

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, phase III clinical trial (UNCOVER-3)

10.1016/j.jaad.2017.04.445 ◽

2017 ◽

Vol 76 (6) ◽

pp. AB112 ◽

Cited By ~ 1

Keyword(s):

Clinical Trial ◽

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Phase Iii Clinical Trial ◽

Faculty Opinions recommendation of Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725781037.793521633 ◽

2016 ◽

Author(s):

Gil Yosipovitch ◽

Leigh Nattkemper

Keyword(s):

Randomized Controlled Trial ◽

Plaque Psoriasis ◽

Controlled Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Phosphodiesterase 4 Inhibitor

Efficacy and safety of efalizumab in patients with moderate to severe plaque psoriasis*1Pooled results from three phase III randomized, placebo-controlled trials

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2004.01.713 ◽

2004 ◽

Vol 113 (2) ◽

pp. S335

Author(s):

A NAYAK

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Controlled Trials ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Three Phase